Newsfiscal.ai
Artiva Biotherapeutics Pauses Phase 3 Trial Following Patient Death
· Published
Article summary
Artiva Biotherapeutics has paused enrollment and dosing in its Phase 3 clinical trial at the request of the FDA following a patient death.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…